Thrombotic activation before and after total hip arthroplasty. A prospective cohort study

• Published in: BMC musculoskeletal disorders Vol. 22; no. 1; pp. 691 - 7
• Main Authors: Burbul, Marta, Tomaszewski, Dariusz, Rogalska, Anna, Gawroński, Krzysztof, Literacki, Sławomir, Waśko, Marcin
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.08.2021; BioMed Central; BMC
• Subjects: Acids; Acute phase proteins; Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Hip - adverse effects; Blood; Blood clotting disorders; Blood loss; Blood Loss, Surgical; Body mass index; Clotting; Coagulation factors; Cohort analysis; Complications; Female; Fibrinogen; Hemoglobin; Hip; Humans; Hypothesis testing; Ischemia; Joint replacement surgery; Joint surgery; Laboratories; Middle Aged; Musculoskeletal diseases; Normal distribution; Orthopedics; Osteoarthritis; Patients; Plasma; Prospective Studies; Pulmonary embolisms; Reagents; Risk factors; Statistical analysis; Surgery; Thromboembolism; Total hip arthroplasty; Tranexamic Acid; Venous thromboembolism; Poland; United States > US; Coagulation factors; Total hip arthroplasty; Venous thromboembolism; Blood loss
• ISSN: 1471-2474; 1471-2474
• DOI: 10.1186/s12891-021-04566-1

Total hip arthroplasty (THA) causes acute blood loss. It may lead to a deficiency in coagulation factors, which, in turn, may lead to increased bleeding during the postoperative period. Thirty patients (18 women) with a mean age of 67 years (range: 63-72 years) participated in this prospective diagnostic study. THA was performed without tranexamic acid administration in the perioperative period. Activities of clotting factors II, VIII, X, and fibrinogen concentration were evaluated before surgery, 6 hours after the procedure, 2, 4, and 6 days after the operation. All laboratory tests were performed using ACL TOP 500 CTS analyzer. No thromboembolic complications were noted during hospitalization. Mean fibrinogen concentration was 366 mg/dL before surgery, which decreased to 311 mg/dL 6 hours after the operation and peaked at 827 mg/dL on the 4th day after the procedure. Activities of factors II and X decreased on the second and fourth days after surgery. Although the activity of factor VIII decreased after the procedure, it remained within the normal range. Increased baseline fibrinogen concentrations were observed in 6 out of 30 (20%) patients. Mean blood loss was 1332 mL (range, 183-2479 mL) and did not correlate with changes in clotting factor activities. In patients undergoing THA, fibrinogen acts as an acute-phase protein. Activities of clotting factors II and X normalize within 6 days, and although the activity of factor VIII decreases, it remains within the normal range. The study was pre-registered May 1st, 2020 on ClinicalTrials.gov.